USFDA25 Nov 2025, 04:02 pm
Zydus Lifesciences Receives USFDA Approval for Verapamil Hydrochloride Extended-Release Tablets
AI Summary
Zydus Lifesciences Ltd has received final approval from the USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg, and 240 mg. These tablets are used to lower high blood pressure and reduce the risk of serious heart problems. The production will be done at Zydus Lifesciences Ltd, Baddi, Himachal Pradesh. The group now has 428 approvals and has filed 487 ANDAs since the commencement of the filing process in FY 2003-04. The Verapamil Hydrochloride Extended-Release Tablets had annual sales of USD 24.5 mn in the United States (IQVIA MAT Sept-2025).
Key Highlights
- Zydus Lifesciences receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg, and 240 mg
- Verapamil Hydrochloride Extended-Release Tablets are used to lower high blood pressure and reduce the risk of serious heart problems
- The production will be done at Zydus Lifesciences Ltd, Baddi, Himachal Pradesh
- Zydus Lifesciences now has 428 approvals and has filed 487 ANDAs since the commencement of the filing process in FY 2003-04
- Verapamil Hydrochloride Extended-Release Tablets had annual sales of USD 24.5 mn in the United States (IQVIA MAT Sept-2025)